M&A Deal Summary

Seagen Acquires Cascadian Therapeutics

On January 31, 2018, Seagen acquired life science company Cascadian Therapeutics for 614M USD

Acquisition Highlights
  • This is Seagen’s 1st transaction in the Life Science sector.
  • This is Seagen’s largest (disclosed) transaction.
  • This is Seagen’s 1st transaction in the United States.
  • This is Seagen’s 1st transaction in Washington.

M&A Deal Summary
Date 2018-01-31
Target Cascadian Therapeutics
Sector Life Science
Buyer(s) Seagen
Deal Type Add-on Acquisition
Deal Value 614M USD
Advisor(s) Perella Weinberg Partners (Financial)
Reed Smith
Goodwin Procter (Legal)

Target

Cascadian Therapeutics

Seattle, Washington, United States
Cascadian Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the treatment of cancer. Cascadian Therapeutics was founded in 1985 and is based in Seattle, Washington.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Seagen

Bothell, Washington, United States
Category Company
Founded 1997
Sector Life Science
Revenue 2.0B USD (2022)
DESCRIPTION

Seagen is a biotechnology company provides an antibody-drug conjugate (ADC) technology harnesses the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. Seattle Genetics commercializes ADCETRIS (brentuximab vedotin) for the treatment of several types of CD30-expressing lymphomas. Seattle was founded in 1997 and is based in Bothell, Washington.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (Washington) 1 of 1
Country (United States) 1 of 1
Year (2018) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal